Allogene Therapeutics (ALLO) Prepaid Assets (2018 - 2026)
Allogene Therapeutics (ALLO) posted Prepaid Assets of $6.4 million for Q1 2026, down 15.02% sequentially from $7.5 million in Q4 2025, and down 44.45% YoY from $11.5 million in Q1 2025.
Allogene Therapeutics (ALLO) Prepaid Assets (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Prepaid Assets for 9 years, with the latest figure at $6.4 million in Q1 2026.
- Quarterly Prepaid Assets fell 44.45% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 44.45% YoY) and the FY2025 annual result came in at $7.5 million, down 30.9% from the prior year.
- Prepaid Assets retreated to $6.4 million in Q1 2026 per ALLO's latest filing, from $7.5 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $22.5 million in Q2 2022 and troughed at $6.4 million in Q1 2026.
- A 5-year average of $11.8 million and a median of $10.5 million in 2024 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2024: Prepaid Assets plunged 55.01% in 2023, then jumped 61.67% in 2024.
- Over 5 years, Prepaid Assets stood at $11.5 million in 2022, then dropped by 9.44% to $10.4 million in 2023, then climbed by 4.72% to $10.9 million in 2024, then plunged by 30.9% to $7.5 million in 2025, then decreased by 15.02% to $6.4 million in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $6.4 million, $7.5 million, and $8.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.40 Mn |
| Mar 31, 2026 | 6.41 Mn |
| Dec 31, 2025 | 7.54 Mn |
| Sep 30, 2025 | 8.53 Mn |
| Jun 30, 2025 | 9.54 Mn |
| Mar 31, 2025 | 11.53 Mn |
| Dec 31, 2024 | 10.91 Mn |
| Sep 30, 2024 | 12.85 Mn |
| Jun 30, 2024 | 12.50 Mn |
| Mar 31, 2024 | 10.50 Mn |
| Dec 31, 2023 | 10.42 Mn |
| Sep 30, 2023 | 7.95 Mn |
| Jun 30, 2023 | 10.14 Mn |
| Mar 31, 2023 | 10.24 Mn |
| Dec 31, 2022 | 11.50 Mn |
| Sep 30, 2022 | 16.83 Mn |
| Jun 30, 2022 | 22.54 Mn |
| Mar 31, 2022 | 20.69 Mn |
| Dec 31, 2021 | 14.02 Mn |
| Sep 30, 2021 | 19.37 Mn |